Emmanuel J Favaloro/LinkedIn
Aug 21, 2025, 14:55
Emmanuel Favaloro on DOACs Versus Warfarin in the COVID19 Era
“Did the COVID19 pandemic push the use of DOACs to the lead in the ‘anticoagulant race’, and ahead of warfarin?
Well, yes and no.
Depends on where you live. Check out this Commentary in Seminars in Thrombosis and Hemostasis.
Just released online.
Enjoy!”
Stay informed with Hemostasis Today.
-
Mar 2, 2026, 17:22Hematologists and Oncologists Recognize Their Role in Specialized VA Care Despite Ongoing Knowledge Gaps – JTH
-
Mar 2, 2026, 17:04Fernando Corrales-Medina: An Evidence-Based Platform Promoting Early Recognition and Evaluation of VWD
-
Mar 2, 2026, 16:56Mbunya S. Misiani: Changing the Narrative on Bleeding Disorders Across Africa
-
Mar 2, 2026, 16:51Ofoke Chiamaka: Rehabilitation Is Not Just Muscle Training, It Is Brain Retraining
-
Mar 2, 2026, 16:41Paul Bolaji: Beyond Acute Stroke Care – Independent Integrated Living After Stroke
-
Mar 2, 2026, 16:37Gianluca Franceschini: Precision Medicine Is Only Truly Effective If It Is Inclusive
-
Mar 2, 2026, 16:34Maha Othman: Calling a Guest Editor for Current Opinion in Hematology
-
Mar 2, 2026, 16:30Tareq Abadl: Erythropoiesis – The Cellular Engineering Behind Oxygen Delivery
-
Mar 2, 2026, 16:28Tagreed Alkaltham: Blood Management in Times of Crisis